A detailed history of Janus Henderson Group PLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 5,566,855 shares of LRMR stock, worth $34.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,566,855
Previous 4,377,388 27.17%
Holding current value
$34.7 Million
Previous $31.7 Million 14.89%
% of portfolio
0.02%
Previous 0.02%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.3 - $10.68 $7.49 Million - $12.7 Million
1,189,467 Added 27.17%
5,566,855 $36.5 Million
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $2.26 Million - $3.53 Million
356,423 Added 8.86%
4,377,388 $31.7 Million
Q1 2024

May 15, 2024

BUY
$4.2 - $13.28 $5.8 Million - $18.3 Million
1,379,900 Added 52.25%
4,020,965 $30.5 Million
Q4 2023

Feb 14, 2024

BUY
$2.35 - $4.71 $422,067 - $845,930
179,603 Added 7.3%
2,641,065 $12 Million
Q3 2023

Nov 14, 2023

BUY
$3.08 - $4.49 $3.13 Million - $4.56 Million
1,015,736 Added 70.26%
2,461,462 $9.72 Million
Q2 2023

Aug 14, 2023

BUY
$3.13 - $5.27 $1.17 Million - $1.98 Million
375,295 Added 35.06%
1,445,726 $4.53 Million
Q1 2023

May 15, 2023

BUY
$4.0 - $6.68 $572,648 - $956,322
143,162 Added 15.44%
1,070,431 $4.85 Million
Q4 2022

Feb 14, 2023

BUY
$2.73 - $5.08 $347,444 - $646,526
127,269 Added 15.91%
927,269 $3.83 Million
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $77,925 - $185,392
50,932 Added 6.8%
800,000 $2.57 Million
Q2 2022

Aug 15, 2022

SELL
$1.9 - $3.98 $562,736 - $1.18 Million
-296,177 Reduced 28.34%
749,068 $1.48 Million
Q1 2022

May 16, 2022

BUY
$3.65 - $10.84 $1.13 Million - $3.36 Million
310,133 Added 42.19%
1,045,245 $4.22 Million
Q4 2021

Feb 14, 2022

BUY
$8.86 - $13.47 $832,813 - $1.27 Million
93,997 Added 14.66%
735,112 $7.92 Million
Q3 2021

Nov 16, 2021

BUY
$9.61 - $15.11 $385,889 - $606,742
40,155 Added 6.68%
641,115 $7.46 Million
Q2 2021

Aug 16, 2021

BUY
$8.0 - $15.2 $3.67 Million - $6.97 Million
458,613 Added 322.18%
600,960 $5.89 Million
Q1 2021

May 17, 2021

BUY
$14.61 - $22.19 $52,625 - $79,928
3,602 Added 2.6%
142,347 $2.08 Million
Q4 2020

Feb 16, 2021

SELL
$14.28 - $25.06 $354,915 - $622,841
-24,854 Reduced 15.19%
138,745 $2.97 Million
Q3 2020

Nov 16, 2020

BUY
$10.5 - $17.6 $1.72 Million - $2.88 Million
163,599 New
163,599 $2.54 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $270M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.